Pomalidomide after CAR T-cell therapy for relapsed or refractory B-cell leukemia or lymphoma
Tests pomalidomide after CAR T-cell therapy in adults with returned or non-responding B-cell blood cancers.
Key facts
- Who runs it
- University of Michigan Rogel Cancer Center
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Registry title
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 12 people, planned
- Started
- 26 Aug 2026
- Expected to end
- Aug 2028
- Type of study
- Interventional
- Treatments tested
- Biospecimen Collection
- Pomalidomide
- Record updated
- 15 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose CD19+ B-cell leukemia or lymphoma came back or did not respond to treatment, and who had a commercial CAR T-cell therapy 28 to 56 days ago. They would take pomalidomide pills after CAR T-cell therapy.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- CD19+ B-cell leukemia or lymphoma that came back (relapsed) or did not respond to treatment (refractory), confirmed by tissue or cell tests
- Earlier treatment
- Must have received a commercially available CAR T-cell product approved for this type of cancer, 28 to 56 days before joining. Must not have had other cancer treatment, including chemotherapy, targeted drugs or checkpoint inhibitors, within 28 days before joining. No radiation therapy within 28 days before joining. No stem cell transplant or rescue after the most recent CAR T-cell therapy.
- Biomarker or test result
- CD19-positive (CD19+) cancer cells
Main reasons for not taking part
- Known progressive or refractory disease
- Active CRS, ICANS or graft versus host disease of grade 2 or higher
- Uncontrolled infection, or taking a high steroid dose (0.25 mg/kg/day or more of methylprednisolone equivalent)
- Smoking cigarettes
- Pregnant, or HIV-positive on a PCR test within 8 weeks of screening
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Subject must have had a histologically or cytologically confirmed R/R CD19+ B-cell leukemia or lymphoma and have received a commercially available CAR-T product approved to treat R/R CD19+ Bcell leukemias and lymphomas
- Subject must be 28 - 56 days post infusion of CD19CART product at time of enrollment
- >= 18 years in age at time of enrollment
- Subject is able to swallow pills/tablets
- Karnofsky performance score of >= 50%
- Absolute neutrophil count (ANC) >= 750/mm\^3 (granulocyte colony stimulating factor allowed)
- Platelets >= 50,000/mm\^3 (transfusion independent for >= 7 days, defined as not receiving platelet transfusions for at least 7 days prior to enrollment, unless due to marrow involvement from primary malignancy [thrombopoietin (TPO) mimetics allowed])
- Total bilirubin =< 1.5 x upper limit of normal (ULN) per institution
- Alanine aminotransferase (ALT [serum glutamate pyruvate transaminase (SGPT)]) =< 3 x institutional ULN per institution
- Serum albumin >= 2.0 g/dL
- Creatinine clearance (Cockcroft-Gault equation) >= 30 mL/min/1.73 m\^2
- Sexually active females capable of becoming pregnant and males must agree to participate in the pomalidomide Risk Evaluation and Mitigation Strategy (REMS) program
- Patients must agree not to donate blood during treatment with pomalidomide and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to pomalidomide
- Co-Enrollment: Willingness to consent/ co-enroll on BMT long term follow up study, HUM00043287 (UMCC2001-0234)
Who cannot take part
- Subject receiving >= 0.25 mg/kg/day of methylprednisolone equivalent. Subject being treated with medications with a known major drug interaction to pomalidomide. Specifically, patients receiving CYP1A2 inhibitors, such as ciprofloxacin, omeprazole, cimetidine, estrogen, and fluvoxamine
- Subject must not have initiated or received intervening therapy for a primary or secondary malignancy within 28 days of study enrollment, including, a) myelosuppressive chemotherapy, b) biologic anti-neoplastic agents (e.g., ruxolitinib, imatinib, dasatinib…), or checkpoint inhibitors (e.g., pembrolizumab). The use of cytokine inhibition for management of CRS/ICANS is allowed within the prior 28 days
- Receipt of radiation therapy (XRT) (focal or large field, including cranial or cranial-spinal) within 28 days prior to enrollment
- Stem cell transplant or rescue following most recent CD19CART therapy
- Intercurrent illness or conditions:; Patients with uncontrolled infections. In addition, patients with any documented bacteremia, fungemia, or new onset viremia that requires antimicrobial therapy within 72 hours prior to enrollment. Empiric antimicrobials are allowed; Active grade >= 4 gastrointestinal, hepatic, pulmonary, renal, cardiac toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 criteria. Patients requiring dialysis are excluded; Patients with concomitant genetic syndromes associated with bone marrow failure states: such as patients with Fanconi anemia, severe congenital neutropenia, Schwachman syndrome or any other known bone marrow failure syndrome. Patients with Down syndrome are not excluded; History of known prior arterial thromboembolism, venous thromboembolism, pulmonary embolism, cardiovascular accidents, or myocardial infarctions within 3 months prior to enrollment
- Pregnant women are excluded from this study. Women should discontinue breastfeeding during treatment and for at least 4 weeks after discontinuation of study drug
- Patients with known progressive or refractory disease
- The following transplant or CAR T-related events are excluded:; Active grade >= 2 acute or chronic graft versus host disease (GVHD); Active cytokine release syndrome (CRS) grade >= 2; Active immune effector cell associated neurotoxicity (ICANS) grade >= 2
- History of allergic reactions to pomalidomide or any of the excipients and any similar compounds
- HIV positivity within 8 weeks of screening on polymerase chain reaction (PCR) based assay
- Patient who smokes cigarettes
Where in United States
- University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: Jennifer E. AgrusaTaking people
About the trial
What the trial wants to find out
This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after a period of improvement (relapsed) or do not respond to treatment (refractory). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells and are then re-infused into the patient. Following CAR T-cell infusion, CAR T-cells must expand and persist in the blood stream in order to most effectively treat leukemia/lymphoma. Pomalidomide stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Research has shown that drugs like pomalidomide can modify the immune system and increase the number or improve the function of CAR T-cells in the blood. Pomalidomide may enhance the treatment effects of CAR T-cell therapy in patients who have received CD19CART therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.
The group in the trial
- Treatment (pomalidomide)Treatment being tested
Patients receive pomalidomide PO QD for 10 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples on study.
Treatment: Biospecimen Collection and Pomalidomide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-Center, Single-Arm, Phase 1 Pilot Study of Pomalidomide Following CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory CD19+ B-Cell Leukemias and Lymphomas
- Plain-language title
- Pomalidomide after CAR T-cell therapy for relapsed or refractory B-cell leukemia or lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 October 2026